AMGN vs GILD — Key Metrics
| Metric | AMGN (AMGEN INC) | GILD (GILEAD SCIENCES INC) |
|---|---|---|
| Price | 443.89 | 168.98 |
| Market Cap | 240.11 Billion | 209.59 Billion |
| P/E (TTM) | 25.54 | -54.51 |
| P/B (Quarterly) | 18.033 | 16.235 |
| P/S (TTM) | 6.17 | 6.76 |
| Net Profit Margin (TTM) | 24.1 | -12.5 |
| Gross Margin (TTM) | 70.9 | 79.9 |
| ROE (TTM) | 85.6 | -21.7 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Outperform
Recommendation Summary
Both stocks are projected to outperform the market over the next year. If you have to make a choice, Upfront Recommendation: GILD.
Financial Metrics
| AMGN | Metrics | GILD |
|---|---|---|
| $443.89 | Price | $168.98 |
| — | Market Capitalization | — |
| 6.17 | Price to Sales | 6.76 |
| 25.06 | Price to FCF Ratio | 15.21 |
| 8.7 | Price to Gross Profit | 8.46 |
| 30.63 | Price to R&D | 33.12 |
| 6.99 | Price to Current Assets | 12.66 |
AMGN vs GILD at a glance
Amgen INC (AMGN) and Gilead Sciences INC (GILD) are both Drug Manufacturers - General companies in the Healthcare sector. They are similar in size: $240.1 billion and $209.6 billion in market value.
On trailing-twelve-month figures, AMGN trades at 6.2 times trailing sales and GILD at 6.8; net profit margins are 24.1% and -12.5%.
The Upfront Investment model currently rates both Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.